When does superficial bladder cancer resist intravesical therapy?
Vögeli
T
T
Department of Urology, University of Düsseldorf, Federal Republic of Germany.
Ackermann
R
R
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology; D014516:Ureteral Neoplasms / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy
D000970:Antineoplastic Agents; D001500:BCG Vaccine